Long Noncoding RNAs in Cholangiocarcinoma

Merdrignac, Aude; Papoutsoglou, Panagiotis; Coulouarn, Cédric

doi:10.1002/hep.31534

Cited by 12 publications

(5 citation statements)

References 97 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the last decade, it was found that many dysregulated lncRNAs in CCA tissues and cells were linked to the pathological characteristics and prognosis of patients with cholangiocarcinoma ( Merdrignac et al, 2021 ). Xie et al (2021) established a prediction model with five lncRNAs (HULC, AL359715.5, AC006504.8, AC090114.2, and AP00943.4) to distinguish the CCA patients with poor prognosis.…”

Section: Lncrnas As Diagnostic and Prognostic Biomarkers In Cholangio...mentioning

confidence: 99%

Long Non-Coding RNAs as Molecular Biomarkers in Cholangiocarcinoma

Khizar

et al. 2022

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Cholangiocarcinoma (CCA) is a biliary system cancer that has the characteristics of strong invasiveness, poor prognosis, and few therapy choices. Furthermore, the absence of precise biomarkers for early identification and prognosis makes it hard to intervene in the early phase of initial diagnosis or recurring cholangiocarcinoma following surgery. Encouragingly, previous studies found that long non-coding RNA (lncRNA), a subgroup of RNA that is more than 200 nucleotides long, can affect cell proliferation, migration, apoptosis, and even drug resistance by altering numerous signaling pathways, thus reaching pro-cancer or anti-cancer outcomes. This review will take a retrospective view of the recent investigations on the work of lncRNAs in cholangiocarcinoma progression and the potential of lncRNAs serving as promising clinical biomarkers and therapeutic targets for CCA.

show abstract

Section: Lncrnas As Diagnostic and Prognostic Biomarkers In Cholangio...mentioning

confidence: 99%

Long Non-Coding RNAs as Molecular Biomarkers in Cholangiocarcinoma

Khizar

et al. 2022

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

show abstract

“…In addition to its insidious onset, CCA is also characterized by high malignancy and early recurrence [23][24][25]28] . Studies have reported that lncRNAs are crucial regulators of diverse biological processes of mRNA and play essential roles in tumorigenesis [29][30][31][32] . Therefore, in this study, we aimed at identifying prognostic-related DElncRNAs in CCA and validated their effects on CCA tumorigenesis and progression.…”

Section: Discussionmentioning

confidence: 99%

Identification and Validation of lncRNA-Related Prognostic Signatures in Cholangiocarcinoma

Zhang

Huang

et al. 2021

Preprint

View full text Add to dashboard Cite

Background and Aims: Cholangiocarcinoma (CCA), the second most common hepatobiliary cancer, is associated with poor prognosis. Therefore, there is a need to elucidate on the pathogenic mechanisms of CCA. In this study, we aimed at identifying lncRNA-related prognostic signatures for CCA through bioinformatics analysis and further validated their functions in CCA tumorigenesis and progression.Methods: The RNA-seq data of CCA were downloaded from public databases. Differentially expressed lncRNAs (DElncRNAs) were screened using R packages. Then, candidate OS- and DFS-related DElncRNAs were selected through Kaplan–Meier survival analysis. Furthermore, LASSO regression analyses were performed to establish two prognostic signatures, termed the OS and DFS signatures, respectively. Multivariate COX models and nomograms for overall survival (OS) and disease-free survival (DFS) were established based on OS/DFS signature and clinical data. Hub lncRNAs were identified and enrichment analyses performed to explore their potential functions. Finally, in vitro and in vivo models were used to validate the effects of the hub lncRNAs in CCA tumorigenesis and progression.Results: A total of 925 DElncRNAs were selected, from which six candidate OS-related lncRNAs and 15 candidate DFS-related lncRNAs were identified. The OS and DFS signatures were then established using four lncRNAs, respectively. We found that the OS signature and vascular invasion were significant independent risk factors for OS outcomes of CCA, while the DFS signature, vascular invasion and CA19-9 were significant independent risk factors for DFS outcomes of CCA. MiR4435-2HG and GAPLINC were selected as hub lncRNAs because they were included in both OS and DFS signatures. GO and KEGG enrichment analyses revealed that the two hub lncRNAs were involved in CCA tumorigenesis and progression. Finally, we constructed in vitro and in vivo models and revealed that the lncRNAs, MiR4435-2HG and GAPLINC can prompt CCA proliferation and migration in vitro and in vivo.Conclusions: The established OS and DFS signatures, which were based on DElncRNAs, are independent risk factors for OS and DFS of CCA patients, respectively. MIR4435-2HG and GAPLINC were identified as hub lncRNAs. In vitro and in vivo models revealed that MiR4435-2HG and GAPLINC can prompt CCA progression, which might be novel prognostic biomarkers and therapeutic targets for CCA.

show abstract

“…Over the last decade, non-coding RNAs (ncRNAs) have emerged as possible new clinically relevant biomarkers to assist in the diagnosis and also in the prognosis of multiple cancers 17 18. Among ncRNAs, microRNAs (miRNAs), long ncRNAs and circular RNAs are the most studied in CCA 19 20.…”

Section: Tissue Biomarkers For Diagnosismentioning

confidence: 99%

Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directions

Macı́as

Cardinale

Kendall

et al. 2022

Gut

Self Cite

View full text Add to dashboard Cite

Cholangiocarcinoma (CCA) is a malignant tumour arising from the biliary system. In Europe, this tumour frequently presents as a sporadic cancer in patients without defined risk factors and is usually diagnosed at advanced stages with a consequent poor prognosis. Therefore, the identification of biomarkers represents an utmost need for patients with CCA. Numerous studies proposed a wide spectrum of biomarkers at tissue and molecular levels. With the present paper, a multidisciplinary group of experts within the European Network for the Study of Cholangiocarcinoma discusses the clinical role of tissue biomarkers and provides a selection based on their current relevance and potential applications in the framework of CCA. Recent advances are proposed by dividing biomarkers based on their potential role in diagnosis, prognosis and therapy response. Limitations of current biomarkers are also identified, together with specific promising areas (ie, artificial intelligence, patient-derived organoids, targeted therapy) where research should be focused to develop future biomarkers.

show abstract

Long Noncoding RNAs in Cholangiocarcinoma

Cited by 12 publications

References 97 publications

Long Non-Coding RNAs as Molecular Biomarkers in Cholangiocarcinoma

Long Non-Coding RNAs as Molecular Biomarkers in Cholangiocarcinoma

Identification and Validation of lncRNA-Related Prognostic Signatures in Cholangiocarcinoma

Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directions

Contact Info

Product

Resources

About